Biotech News
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that seven abstracts have been accepted for poster presentation at the 33 rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany.